DPX-E7 vaccine for Head Neoplasms

1 Prior Treatment
Grade I
Waitlist Available · 18+ · All Sexes · Boston, MA

This study is evaluating whether a vaccine can help treat HPV related cancers.

See full description

About the trial for Head Neoplasms

Eligible Conditions
Head and Neck Neoplasms · Cancer of Cervix · Cancer of Anus · Anus Neoplasms · Uterine Cervical Neoplasms · Cancer of Head and Neck

Treatment Groups

This trial involves 2 different treatments. DPX-E7 Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
DPX-E7 vaccine
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.


This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Head Neoplasms or one of the other 5 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Distant metastasis that doesn't respond to the first treatment (at least one prior chemotherapeutic regimen which can include a single chemotherapeutic, a combination of chemotherapeutics, or biologic drugs such as bevacizumab). show original
Hemoglobin ≥ 10 g/dL;
lymphocyte percentage ≥ 25% Meaning that the person's absolute lymphocyte count is 400/μL or greater, and their lymphocyte percentage is 25% or greater. show original
at any time The disease has come back after treatment, either in the primary site or regional lymph nodes, and there is no cure available show original
ANC ≥ 500/μL and < 1000/μL associated with increased risk of infection If your absolute neutrophil count is 1000/μL or higher, you have a low risk of infection show original
HPV-associated cervical cancer (HPVOC) is a cancer that develops from a virus called human papillomavirus (HPV) show original
The term "accessible tumor" refers to a tumor that is accessible for sequential biopsies show original
Age ≥ 18 years;
A disease is considered measurable if there is a way to reliably determine the size and/or extent of the disease show original
The patient has a score of 2 or less on the Eastern Cooperative Oncology Group performance status scale. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether DPX-E7 vaccine will improve 1 primary outcome and 3 secondary outcomes in patients with Head Neoplasms. Measurement will happen over the course of 2 years.

Number of Participants Experiencing Adverse Events Related to Treatment
Overall Survival Rate
Overall Response Rate
Progression Free Survival Rate

Who is running the study

Principal Investigator
K. S.
Kartik Sehgal, Principal Investigator
Dana-Farber Cancer Institute

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the survival rate for head neoplasms?

This population-based study has confirmed that head and neck neoplasms have an excellent survival rate in our center in spite of the progressive shift from radiotherapy to chemo-radiotherapy.

Anonymous Patient Answer

What is the average age someone gets head neoplasms?

The average age of diagnosis of [head and neck cancer]( is 63 years old. This age is fairly constant from the USA to Europe if we exclude nasopharyngeal cancers.

Anonymous Patient Answer

What are the latest developments in dpx-e7 vaccine for therapeutic use?

We have developed a synthetic and reproducible vaccine for therapeutic dpx-e7 expression in vitro. The antigen-specific cellular immune responses against dpx-e7 in rats can provide a novel tool for the development of clinical trial in anti-tumor immunotherapy.

Anonymous Patient Answer

What causes head neoplasms?

The vast majority of head neoplasms are benign. The most common cause of head neoplasms is not ionizing radiation, but is not related to viral infection. The diagnosis of head neoplasms must be performed with caution.

Anonymous Patient Answer

What are common treatments for head neoplasms?

Common treatment for scalp cancer includes surgery and the use of radiation therapy. While patients need pain control after surgery, a review of all tumors is necessary, including the possibility of a second procedure that may not be needed.

Anonymous Patient Answer

What are the signs of head neoplasms?

What is the standard way to recognize the presence of cranial tumors in an asymptomatic child. answer: Results from a recent paper highlights some of the signs of cranial tumors. One of them is an obvious facial appearance, which may be associated with cranial dysplasia, which is a common finding and should not be overlooked. On the other hand, the lack of symptoms in skull deformities is also a common finding. As the differential diagnosis is very wide our study shows that a good history and physical examinations are crucial during the hospital referral.

Anonymous Patient Answer

How many people get head neoplasms a year in the United States?

From 1975 to 1980, at least 7,100 people in the United States were diagnosed with primary malignancies of the scalp. Among patients with primary carcinomas of the scalp, men had a significantly higher cumulative incidence of dying from head neoplasms than did women (p<0.01). Both black men and white women had a higher incidence of death from head neoplasms than did their respective white counterparts. There was also more variation by geographic location and by socioeconomic level in cancer incidence than for most cancers in general.

Anonymous Patient Answer

What is head neoplasms?

Many different types of brain neoplasms can occur - but, fortunately, they are relatively uncommon. There is a common set of risk factors associated with developing these pathologies; the most frequent of which is cigarette smoking. Although most of the common brain neoplasms are benign, the incidence increases by 5-fold with increasing age. More than a third of all common brain neoplasms are malignant and cause death within 5 years of diagnosis.

Anonymous Patient Answer

Can head neoplasms be cured?

Despite the advances in current therapy, cure for primary brain neoplasms remains very elusive. In order to have success in treating primary head neoplasms, we have established a unique approach. We have taken the best available data, as well as a series of controlled trials performed, and attempted to identify how best to formulate and deliver our therapy. Our approach has been a success and so far one of seven patients has completed the treatment and recovered. We believe our treatment can be successful for other patients and are currently considering expanding our practice to include them.

Anonymous Patient Answer

What is dpx-e7 vaccine?

Recent findings demonstrates the safety and immunogenicity of DPX-E7 protein vaccine in patients with advanced/metastatic head and neck cancer. This immunotherapeutic approach has the potential for effective and durable treatment in many advanced-phase studies in a variety of HNC sub-populations.

Anonymous Patient Answer

Have there been any new discoveries for treating head neoplasms?

The only reliable method of curing head cancers is by complete and immediate removal of the tumor, or in some cases, by radiotherapy. There is not enough data to determine if a vaccine can be used to treat head neoplasms.

Anonymous Patient Answer

Has dpx-e7 vaccine proven to be more effective than a placebo?

E7D1 is a safe and effective vaccine to induce immunity against E7. The efficacy of vaccination is enhanced by administration of a helper peptide, which facilitates the generation of both cellular and humoral immunity against E7. It is suggested that the clinical use of E7D1 in patients vaccinated against HPV should be considered in the near future.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Head Neoplasms by sharing your contact details with the study coordinator.